フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...
333-156660 SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services Judges highlight value-added partnership and finance...
New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S. Results of retrospective analysis...
UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015 PR Newswire ATLANTA, May 16, 2015 ATLANTA, May 16, 2015...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. FORM...
UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam - Major milestone for brivaracetam is latest...
UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annual Meeting PR...
UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset...
UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care - Atlanta-based Collaboration Will...
UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES) - 24 UCB-sponsored presentations...
UCB shows strong scientific presence at leading rheumatology meeting -- Data to be presented at the ACR/ARHP Annual Meeting on UCB's marketed...
Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB PR Newswire BOSTON and NEW YORK, Nov. 7, 2014...
As filed with the Securities and Exchange Commission on October 31, 2014 Registration No...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約